TY  - JOUR
PB  - Clinical and Experimental Rheumatology Sas
UR  - https://doi.org/10.55563/clinexprheumatol/e92f7o
TI  - Canakinumab improves patient-reported outcomes in children and adults with autoinflammatory recurrent fever syndromes: results from the CLUSTER trial
AV  - public
EP  - 58
IS  - 5
KW  - Adult
KW  -  Antibodies
KW  -  Monoclonal
KW  -  Antibodies
KW  -  Monoclonal
KW  -  Humanized
KW  -  Child
KW  -  Humans
KW  -  Patient Reported Outcome Measures
KW  -  Quality of Life
KW  -  Syndrome
A1  - Lachmann, Helen J
A1  - Lauwerys, Bernard
A1  - Miettunen, Paivi
A1  - Kallinich, Tilmann
A1  - Jansson, Annette
A1  - Rosner, Itzhak
A1  - Manna, Raffaele
A1  - Murias, Sara
A1  - Savic, Sinisa
A1  - Smeets, Serge
A1  - De Benedetti, Fabrizio
A1  - Simon, Anna
SP  - 51
N2  - OBJECTIVES: To evaluate the effect of canakinumab on health-related quality of life (HRQoL), work/school and social life of patients with autoinflammatory recurrent fever syndromes, including colchicine-resistant familial Mediterranean fever, mevalonate kinase deficiency, and tumour necrosis factor receptor-associated periodic syndrome, in the CLUSTER trial. METHODS: HRQoL of patients who received canakinumab 150 mg or 300 mg every four weeks in the CLUSTER trial (n=173) was assessed at baseline and Weeks 17 and 41. For children we used the Child Health Questionnaire - Parent Form 50 (CHQ-PF50), including psychosocial (PsS) and physical (PhS) component summary scores. For adults, the Short-Form-12 (SF-12) Health Survey was used, including physical (PFS) and mental (PCS) component summary scores. The Sheehan Disability Scale (SDS) was used to determine the impact of treatment on work/school, social and family life. RESULTS: The results obtained were remarkably consistent in both paediatric and adult patients across the three disease cohorts. At baseline, median scores for physical components were relatively low (26-29 for PhS and 34-38 for PFS); they improved to values similar to those expected in the general population by Week 17, and this improvement was sustained at Week 41, when median PhS scores were 47-50 and PFS 44-54. Psychosocial and mental scores also improved from baseline to Week 17 and 41, with scores comparable to the general population. Notable improvements were also observed in the SDS scale. CONCLUSIONS: Patients with three inherited autoinflammatory syndromes experienced sustained improvements on their HRQoL, work/school, and social life on treatment with canakinumab.
Y1  - 2021/10/06/
JF  - Clinical and Experimental Rheumatology
N1  - This version is the author accepted manuscript. For information on re-use, please refer to the publisher?s terms and conditions.
VL  - 39
ID  - discovery10150380
ER  -